Intuitive Surgical stock: BofA raises price target to $500
Published on 11/17/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBofA shifts its valuation view
- BofA retained its Buy rating while raising its price objective for Intuitive Surgical.
- The analyst action followed the company's third-quarter results and broader debate over medical-technology demand.
On November 10, BofA Securities analyst Travis Steed reaffirmed a Buy rating on Intuitive Surgical and raised the price target from 470 US dollars to 500 US dollars, according to Poisar. The change gives investors a higher sell-side valuation marker while leaving the bank's positive rating unchanged.
What changed in BofA's view
BofA's note points to a less negative mood across medical technology after Intuitive Surgical's third-quarter results and the US election. The bank also sees a possible pause for the group while investors assess whether lower 2027 consensus estimates can be exceeded, according to the cited report.
For Intuitive Surgical, the analyst action keeps attention on procedure growth, system placements and the outlook for the surgical robotics market. It is an external valuation view rather than a change to company guidance, so investors must weigh the higher target against the operating risks already reflected in the post-results debate.
Investor context
The company recently announced that Aaron Martin, Humana's President of Insurance, will join its board on January 1, 2027. That governance change is separate from BofA's valuation action and expands the board's healthcare, payer and digital-health experience.
Intuitive Surgical at a glance
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- Ticker: ISRG
- Analyst action: BofA Securities retained Buy and raised its price target from 470 US dollars to 500 US dollars
- Event date: November 10, 2026
Broader market context is available in Current market reports.
